148 related articles for article (PubMed ID: 31190745)
1. Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study.
Antinori A; Rusconi S; Gianotti N; Bini T; Mancusi D; Termini R
Drug Des Devel Ther; 2019; 13():1667-1685. PubMed ID: 31190745
[No Abstract] [Full Text] [Related]
2. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
Antinori A; Meraviglia P; Monforte Ad; Castagna A; Mussini C; Bini T; Gianotti N; Rusconi S; Colella E; Airoldi G; Mancusi D; Termini R
Drug Des Devel Ther; 2016; 10():1589-603. PubMed ID: 27226708
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
Ryom L; Lundgren JD; El-Sadr W; Reiss P; Kirk O; Law M; Phillips A; Weber R; Fontas E; d' Arminio Monforte A; De Wit S; Dabis F; Hatleberg CI; Sabin C; Mocroft A;
Lancet HIV; 2018 Jun; 5(6):e291-e300. PubMed ID: 29731407
[TBL] [Abstract][Full Text] [Related]
4. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
[TBL] [Abstract][Full Text] [Related]
5. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
Costagliola D; Potard V; Lang S; de Castro N; Cotte L; Duval X; Duvivier C; Grabar S; Mary-Krause M; Partisani M; Ronot-Bregigeon S; Simon A; Tattevin P; Weiss L; Zucman D; Katlama C; Raffi F; Boccara F
J Infect Dis; 2020 Feb; 221(4):516-522. PubMed ID: 31828320
[TBL] [Abstract][Full Text] [Related]
6. Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factor.
Lin KY; Cheng CY; Yang CJ; Tsai MS; Hsieh SM; Sun HY; Sheng WH; Chen MY; Chang SY; Cheng SH; Hung CC
J Infect Chemother; 2014 Aug; 20(8):465-70. PubMed ID: 24855915
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
Rachlis A; Clotet B; Baxter J; Murphy R; Lefebvre E
HIV Clin Trials; 2007; 8(4):213-20. PubMed ID: 17720661
[TBL] [Abstract][Full Text] [Related]
8. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort.
d'Arminio Monforte A; Lorenzini P; Cozzi-Lepri A; Mussini C; Castagna A; Baldelli F; Puoti M; Vichi F; Maddaloni A; Lo Caputo S; Gianotti N; Antinori A;
HIV Clin Trials; 2018 Apr; 19(2):52-60. PubMed ID: 29493419
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
Vingerhoets J; Calvez V; Flandre P; Marcelin AG; Ceccherini-Silberstein F; Perno CF; Mercedes Santoro M; Bateson R; Nelson M; Cozzi-Lepri A; Grarup J; Lundgren J; Incardona F; Kaiser R; Sonnerborg A; Clotet B; Paredes R; Günthard HF; Ledergerber B; Hoogstoel A; Nijs S; Tambuyzer L; Lavreys L; Opsomer M;
HIV Med; 2015 May; 16(5):297-306. PubMed ID: 25585664
[TBL] [Abstract][Full Text] [Related]
10. The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years.
Violari A; Masenya M; Blanche S; Vanveggel S; Hufkens V; Chetty P; Opsomer M
Drug Saf; 2021 Apr; 44(4):439-446. PubMed ID: 33367975
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
Jabłonowska E; Pulik P; Kalinowska A; Gąsiorowski J; Parczewski M; Bociąga-Jasik M; Pulik Ł; Siwak E; Wójcik K
J Med Virol; 2017 Dec; 89(12):2122-2129. PubMed ID: 28390164
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
[TBL] [Abstract][Full Text] [Related]
13. Experience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single center.
Gathe J
Curr Med Res Opin; 2008 Mar; 24(3):769-73. PubMed ID: 18234149
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination.
Augustine R; Ashkenazi DL; Arzi RS; Zlobin V; Shofti R; Sosnik A
Acta Biomater; 2018 Jul; 74():344-359. PubMed ID: 29723705
[TBL] [Abstract][Full Text] [Related]
15. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Maggi P; Bellacosa C; Leone A; Volpe A; Ricci ED; Ladisa N; Cicalini S; Grilli E; Viglietti R; Chirianni A; Bellazzi LI; Maserati R; Martinelli C; Corsi P; Celesia BM; Sozio F; Angarano G
Atherosclerosis; 2017 Aug; 263():398-404. PubMed ID: 28522147
[TBL] [Abstract][Full Text] [Related]
17. Darunavir: A Review in Pediatric HIV-1 Infection.
Keating GM
Paediatr Drugs; 2015 Oct; 17(5):411-21. PubMed ID: 26323490
[TBL] [Abstract][Full Text] [Related]
18. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
Bánhegyi D; Katlama C; da Cunha CA; Schneider S; Rachlis A; Workman C; De Meyer S; Vandevoorde A; Van De Casteele T; Tomaka F
Curr HIV Res; 2012 Mar; 10(2):171-81. PubMed ID: 22339125
[TBL] [Abstract][Full Text] [Related]
19. Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting.
Nishijima T; Gatanaga H; Teruya K; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Kikuchi Y; Oka S
J Infect Chemother; 2014 Apr; 20(4):285-7. PubMed ID: 24507978
[TBL] [Abstract][Full Text] [Related]
20. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
